BACKGROUND: Oncolytic adenoviruses are among the most widely utilized oncolytic viruses due to their notable anti-tumor and gene expression capabilities, and modification of ADVs to create armed adenoviruses remains a popular research direction. Nonetheless, immune suppression triggered by ADV and targeted enhancements based on this limitation have been relatively unexplored. METHODS: Flow cytometry was employed to assess immune infiltration in the tumor microenvironment following ADV therapy. Targeted novel recombinant oncolytic viruses, ADV RESULTS: We demonstrated that ADV limits the infiltration of effector memory/effector CD8 + T cells (T CONCLUSIONS: In summary, this study presents the development of the novel oncolytic adenoviruses ADV